Apo-transferrin (apo-Tf), hepcidin agonists, JAK2 inhibitors, Tmprsso inhibitors, and activin receptor II (ActRII) ligand traps hold promise for improving iron overload management, averting splenomegaly and thrombosis, and decreasing the need for transfusions in individuals with ß-thalassemia [9,11]. This evidence concerns the gene ACVR2A and Splenomegaly.